Gene expression, methylation and neuropathology correlations at progressive supranuclear palsy risk loci
- 1k Downloads
To determine the effects of single nucleotide polymorphisms (SNPs) identified in a genome-wide association study of progressive supranuclear palsy (PSP), we tested their association with brain gene expression, CpG methylation and neuropathology. In 175 autopsied PSP subjects, we performed associations between seven PSP risk variants and temporal cortex levels of 20 genes in-cis, within ±100 kb. Methylation measures were collected using reduced representation bisulfite sequencing in 43 PSP brains. To determine whether SNP/expression associations are due to epigenetic modifications, CpG methylation levels of associated genes were tested against relevant variants. Quantitative neuropathology endophenotypes were tested for SNP associations in 422 PSP subjects. Brain levels of LRRC37A4 and ARL17B were associated with rs8070723; MOBP with rs1768208 and both ARL17A and ARL17B with rs242557. Expression associations for LRRC37A4 and MOBP were available in an additional 100 PSP subjects. Meta-analysis revealed highly significant associations for PSP risk alleles of rs8070723 and rs1768208 with higher LRRC37A4 and MOBP brain levels, respectively. Methylation levels of one CpG in the 3′ region of ARL17B associated with rs242557 and rs8070723. Additionally, methylation levels of an intronic ARL17A CpG associated with rs242557 and that of an intronic MOBP CpG with rs1768208. MAPT and MOBP region risk alleles also associated with higher levels of neuropathology. Strongest associations were observed for rs242557/coiled bodies and tufted astrocytes; and for rs1768208/coiled bodies and tau threads. These findings suggest that PSP variants at MAPT and MOBP loci may confer PSP risk via influencing gene expression and tau neuropathology. MOBP, LRRC37A4, ARL17A and ARL17B warrant further assessment as candidate PSP risk genes. Our findings have implications for the mechanism of action of variants at some of the top PSP risk loci.
KeywordsProgressive supranuclear palsy Epigenetic Transcription Brain tissue Neuropathology traits Association Genetic risk
For the brain donations, we thank all patients and their families, without whom this work would not have been possible. This work is supported in part by Grants from National Institutes of Health, National Institute on Aging (R01 AG032990 and U01 AG046139 to N.E.T); National Institute of Neurological Disorders and Stroke (R01 NS080820 to N.E.T); Cure PSP (to N.E.T and D.W.D); Mayo Clinic Center for Individualized Medicine, Epigenetics Program Grant (to N.E.T and M.A.).
Compliances with ethical standards
Conflict of interest
- 16.Ferrari R, Ryten M, Simone R, Trabzuni D, Nicolaou N, Hondhamuni G et al (2014) Assessment of common variability and expression quantitative trait loci for genome-wide associations for progressive supranuclear palsy. Neurobiol Aging 35(1514):e1511–e1512. doi: 10.1016/j.neurobiolaging.2014.01.010 Google Scholar
- 17.Goedert M (2015) Neurodegeneration. Alzheimer’s and Parkinson’s diseases: the prion concept in relation to assembled Abeta, tau, and alpha-synuclein. Science 349:1255555. doi: 10.1126/science.1255555
- 28.Majercak J, Ray WJ, Espeseth A, Simon A, Shi XP, Wolffe C et al (2006) LRRTM3 promotes processing of amyloid-precursor protein by BACE1 and is a positional candidate gene for late-onset Alzheimer’s disease. Proc Natl Acad Sci 103:17967–17972. doi: 10.1073/pnas.0605461103 CrossRefPubMedPubMedCentralGoogle Scholar
- 31.Pastor P, Moreno F, Clarimon J, Ruiz A, Combarros O, Calero M et al (2015) MAPT H1 haplotype is associated with late-onset Alzheimer’s disease risk in APOEvarepsilon4 noncarriers: results from the Dementia Genetics Spanish Consortium. J Alzheimers Dis 49:343–352. doi: 10.3233/JAD-150555 CrossRefPubMedGoogle Scholar
- 33.Pittman AM, Myers AJ, Abou-Sleiman P, Fung HC, Kaleem M, Marlowe L et al (2005) Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration. J Med Genet 42:837–846. doi: 10.1136/jmg.2005.031377 CrossRefPubMedPubMedCentralGoogle Scholar